AR097648A1 - Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide - Google Patents

Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide

Info

Publication number
AR097648A1
AR097648A1 ARP140103413A ARP140103413A AR097648A1 AR 097648 A1 AR097648 A1 AR 097648A1 AR P140103413 A ARP140103413 A AR P140103413A AR P140103413 A ARP140103413 A AR P140103413A AR 097648 A1 AR097648 A1 AR 097648A1
Authority
AR
Argentina
Prior art keywords
target
epigenetic
factor
compound
inhibitors
Prior art date
Application number
ARP140103413A
Other languages
English (en)
Inventor
Subklewe Marion
Krupka Christina
B Walter Roland
Original Assignee
Amgen Inc
Amgen Res (Munich) Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Amgen Res (Munich) Gmbh filed Critical Amgen Inc
Publication of AR097648A1 publication Critical patent/AR097648A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Abstract

Una combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana CD33 y CD3 en el tratamiento de leucemia mieloide, en donde el factor epigenético está seleccionado del grupo que consiste de inhibidores de histona desacetilasa (HDAC), inhibidores de ADN metiltransferasa (DNMT) I, hidroxiurea, Factor Estimulante Colonia de Granulocitos (G-CSF), inhibidores de histona desmetilasa y ATRA (ácido todo-trans-retinoico). Una composición farmacéutica que comprende un compuesto que tienen como diana CD33 y al menos un factor epigenético. Un factor epigenético para uso en la mejora y/o tratamiento de una leucemia mieloide, en donde el factor epigenético aumenta la respuesta de un paciente a un compuesto que tiene como diana CD33. Uso de al menos un factor epigenético para incrementar el grado de respuesta de un paciente con leucemia mieloide a un tratamiento con un compuesto que tiene como diana CD33, un método para el tratamiento de una leucemia mieloide, que comprende la administración de al menos un factor epigenético y un compuesto que tiene como diana CD33 a un paciente en necesidad del mismo y un kit que comprende una composición farmacéutica de la presente o un factor epigenético de la presente y un compuesto biespecífico que tiene como diana CD33. Reivindicación 1: Una composición farmacéutica que comprende un compuesto que tienen como diana CD33 y al menos un factor epigenético, en donde (a) el compuesto que tiene como diana CD33 es un constructo biespecífico que comprende un primer dominio de unión que se une específicamente a CD33 y un segundo dominio de unión que se une específicamente a CD3; y (b) el al menos un factor epigenético está seleccionado del grupo que consiste de inhibidores de histona desacetilasa (HDAC), inhibidores de ADN metiltransferasa (DNMT) I, hidroxiurea, Factor Estimulante Colonia de Granulocitos (G-CSF), inhibidores de histona metiltransferasa (HMT) y ATRA (ácido todo-trans-retinoico). Reivindicación 2: La composición farmacéutica de la reivindicación 1, en donde el al menos un factor epigenético está seleccionado del grupo que comprende (a) un inhibidor de histona desacetilasa (HDAC) seleccionado del grupo que consiste de panobinostat, vorinostat, romidepsin, N-acetildinalina, belinostat, givinostat, entinostat, mocetinostat, EVP-0334, SRT501, CUDC-101, Quisinostat, abexinostat, LAQ824, y ácido valproico; (b) un inhibidor de ADN metiltransferasa (DNMT) l seleccionado del grupo que consiste de 5-azacitidina, decitabina, hidralazina, zebularina, procainamida, (-)-epigalocatequin-3-galato, MG98, RG108, y SGI-110; y (c) un inhibidor de histona metiltransferasa (HMT) seleccionado del grupo que consiste de un inhibidor de LSD1 (KDM1A) desmetilasa, y quetocina.
ARP140103413A 2013-09-13 2014-09-12 Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide AR097648A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361877714P 2013-09-13 2013-09-13

Publications (1)

Publication Number Publication Date
AR097648A1 true AR097648A1 (es) 2016-04-06

Family

ID=51690351

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140103413A AR097648A1 (es) 2013-09-13 2014-09-12 Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide

Country Status (28)

Country Link
US (1) US10933132B2 (es)
EP (1) EP3043794B1 (es)
JP (1) JP6530409B2 (es)
KR (1) KR102366470B1 (es)
CN (2) CN111888474A (es)
AP (1) AP2016009132A0 (es)
AR (1) AR097648A1 (es)
AU (2) AU2014320246B2 (es)
CA (1) CA2923354C (es)
CL (1) CL2016000564A1 (es)
DK (1) DK3043794T3 (es)
EA (1) EA036476B1 (es)
HK (1) HK1225975A1 (es)
HU (1) HUE056867T2 (es)
IL (1) IL278527B (es)
JO (1) JO3597B1 (es)
LT (1) LT3043794T (es)
MA (2) MA46164B1 (es)
MX (1) MX2016003197A (es)
MY (1) MY185611A (es)
NZ (1) NZ716448A (es)
PH (1) PH12016500434A1 (es)
SG (2) SG10201801777YA (es)
SI (1) SI3043794T1 (es)
TW (1) TWI688401B (es)
UA (1) UA123199C2 (es)
WO (1) WO2015036583A2 (es)
ZA (1) ZA201600528B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9212225B1 (en) 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
EP3302555A4 (en) * 2015-05-29 2018-07-11 Amphivena Therapeutics, Inc. Methods of using bispecific cd33 and cd3 binding proteins
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
EP3390653B1 (en) 2015-12-16 2022-08-10 F. Hoffmann-La Roche AG Improved recombinant production method
TWI797073B (zh) * 2016-01-25 2023-04-01 德商安美基研究（慕尼黑）公司 包含雙特異性抗體建構物之醫藥組合物
EA039859B1 (ru) * 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
JOP20170091B1 (ar) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
DK3600419T5 (en) * 2017-03-20 2023-11-13 Vaccinex Inc Treatment of cancer with a semaphorin-4d antibody in combination with an epigenetic modulating agent
KR102090407B1 (ko) * 2017-11-24 2020-03-17 충북대학교 산학협력단 항-icam4 항체 및 icam4 발현 세포와 관련된 질병의 진단 및 치료용 조성물
WO2019103531A1 (ko) * 2017-11-24 2019-05-31 충북대학교 산학협력단 항-icam4 항체 및 icam4 발현 세포와 관련된 질병의 진단 및 치료용 조성물
US11597933B2 (en) 2017-11-29 2023-03-07 The Trustees Of Columbia University In The City Of New York Combination therapy of lymphoma
JOP20190116A1 (ar) 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
TW202021616A (zh) * 2018-07-30 2020-06-16 美商安進公司 結合至ｃｄ３３和ｃｄ３的雙特異性抗體構建體之延長投與
US20220098613A1 (en) 2018-09-12 2022-03-31 Fred Hutchinson Cancer Research Center Reducing cd33 expression to selectively protect therapeutic cells
CN113045664B (zh) 2019-11-28 2023-05-12 尚健单抗（北京）生物技术有限公司 一种分离的结合抗原axl的蛋白及其用途
JP2023506458A (ja) 2019-12-09 2023-02-16 北京中因科技有限公司 医薬の製造におけるＣＹＰ４Ｖ２およびＲｄＣＶＦの使用
CN112079934B (zh) 2019-12-17 2021-01-29 合源生物科技(天津)有限公司 一种靶向cd19的嵌合抗原受体及其用途
CA3163304A1 (en) 2020-01-02 2021-07-08 Xiaoyun SHANG Modified immune effector cell and preparation method therefor
CN113481165B (zh) * 2020-07-16 2022-06-03 山东博安生物技术股份有限公司 分泌双特异性t细胞衔接子的car-t及治疗实体肿瘤的应用
CN111733174B (zh) 2020-08-07 2021-02-09 北京大学第三医院（北京大学第三临床医学院） 一种分离的核酸分子及其用途
TW202222840A (zh) 2020-12-11 2022-06-16 大陸商上海華奧泰生物藥業股份有限公司 Ｃｄ７３的抗原結合蛋白及其應用
US20240059764A1 (en) 2021-01-11 2024-02-22 Starmab Biologics (Suzhou) Co., Ltd. ANTIGEN-BINDING PROTEIN TARGETING STAPHYLOCOCCUS AUREUS a-HEMOLYSIS AND APPLICATION THEREOF
AU2022207557A1 (en) 2021-01-13 2023-07-06 Huabo Biopharm (Shanghai) Co., Ltd. Cd73-binding protein and use thereof
CN112630438B (zh) * 2021-03-08 2021-06-22 信纳克(北京)生化标志物检测医学研究有限责任公司 抗体组合物及其筛查髓系疾病及检测免疫检查点的应用
KR20230162797A (ko) 2021-03-22 2023-11-28 스타맵 바이오로직스 (쑤저우) 씨오., 엘티디 뉴몰리신을 표적으로 하는 항원 결합 단백질 및 이의 용도
EP4299593A1 (en) 2021-04-02 2024-01-03 Oricell Therapeutics Co., Ltd. Cldn18.2 antigen-binding protein and use thereof
CN113533729A (zh) * 2021-06-15 2021-10-22 北京大学人民医院 一种鉴定aml患者骨髓中nk细胞耗竭的研究方法及其应用
CN115612674A (zh) 2021-07-14 2023-01-17 上海荣瑞医药科技有限公司 一种溶瘤病毒及其用途
CN113461821B (zh) * 2021-09-03 2021-12-28 苏州近岸蛋白质科技股份有限公司 抗cd3人源化抗体
CN114908087B (zh) * 2022-05-07 2024-01-23 四川大学华西医院 一种长循环肾靶向细胞外囊泡的构建及其应用

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
DE69131780T2 (de) 1991-03-11 2000-11-16 Univ Georgia Res Foundation At Klonierung und expression der luziferase aus renilla
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
DE69332981T2 (de) 1992-10-23 2004-05-19 Immunex Corp., Seattle Methoden zur herstellung löslicher, oligomerer proteine
CA2169298A1 (en) 1993-09-10 1995-03-16 Martin Chalfie Uses of green fluorescent protein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
ATE290205T1 (de) 1996-12-12 2005-03-15 Prolume Ltd Vorrichtung und verfahren zum nachweis und identifizieren von infektiösen wirkstoffen
CA2324648C (en) 1998-03-27 2013-02-26 Prolume, Ltd. Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
JP4169478B2 (ja) 1998-04-21 2008-10-22 マイクロメット アーゲー Ｃｄ１９×ｃｄ３特異的ポリペプチドおよびその使用
US20050025823A1 (en) * 2003-07-29 2005-02-03 Fong Andy A.T. Methods of use of herbal compositions
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS
CA2625440C (en) 2005-10-11 2023-06-13 Micromet Ag Compositions comprising cross-species-specific antibodies and uses thereof
JP2010509234A (ja) * 2006-11-02 2010-03-25 シアトル ジェネティックス， インコーポレイテッド 新生物疾患、自己免疫疾患および炎症性疾患を処置する方法
JP2010524851A (ja) * 2007-04-03 2010-07-22 マイクロメット アーゲー 種間特異的結合ドメイン
UA112062C2 (uk) * 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
WO2015036583A2 (en) 2015-03-19
WO2015036583A3 (en) 2015-07-02
CA2923354C (en) 2022-11-29
MX2016003197A (es) 2016-06-02
LT3043794T (lt) 2021-10-25
SG11201600671QA (en) 2016-02-26
KR20160058120A (ko) 2016-05-24
AP2016009132A0 (en) 2016-04-30
US20160317657A1 (en) 2016-11-03
DK3043794T3 (da) 2021-11-15
TWI688401B (zh) 2020-03-21
IL278527B (en) 2022-07-01
PH12016500434B1 (en) 2016-05-16
EP3043794A2 (en) 2016-07-20
SI3043794T1 (sl) 2021-11-30
MA46164B1 (fr) 2021-04-30
MA46164A1 (fr) 2020-12-31
JO3597B1 (ar) 2020-07-05
US10933132B2 (en) 2021-03-02
HK1225975A1 (zh) 2017-09-22
MY185611A (en) 2021-05-25
CN105764505A (zh) 2016-07-13
JP2016536341A (ja) 2016-11-24
AU2014320246B2 (en) 2020-01-23
SG10201801777YA (en) 2018-04-27
EA036476B1 (ru) 2020-11-13
IL278527A (es) 2020-12-31
PH12016500434A1 (en) 2016-05-16
ZA201600528B (en) 2021-06-30
AU2014320246A1 (en) 2016-02-18
JP6530409B2 (ja) 2019-06-12
NZ716448A (en) 2022-02-25
CA2923354A1 (en) 2015-03-19
EP3043794B1 (en) 2021-09-01
CL2016000564A1 (es) 2017-03-24
AU2020202641A1 (en) 2020-05-14
CN111888474A (zh) 2020-11-06
UA123199C2 (uk) 2021-03-03
MA38898A1 (fr) 2018-01-31
EA201690485A1 (ru) 2016-08-31
TW201605473A (zh) 2016-02-16
HUE056867T2 (hu) 2022-03-28
KR102366470B1 (ko) 2022-02-24

Similar Documents

Publication Publication Date Title
AR097648A1 (es) Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
JP2016536341A5 (es)
BR112017000301A2 (pt) tratamento de leucemia com inibidores de histona desacetilase
BR112018075998A2 (pt) composições antifúngicas sinérgicas e métodos das mesmas
CO2017004002A2 (es) Moléculas multiespecíficas que se unen a glipicano-3 y al complejo receptor de células t
CL2019003283A1 (es) Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas.
CL2017001488A1 (es) Benzamidas sustituidas con 1,3–tiazol–2–ilo
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
BR112017018941B8 (pt) Molécula de ligação a cd20, seu uso, composição e método in vitro para direcionar a morte mediada por complemento de uma célula que expressa cd20
CR20160173A (es) Nuevo tratamiento de combinación para la leucemia mieloide aguda (lma)
CL2015002394A1 (es) Inhibidores de histona desmetilasas
EA201690080A1 (ru) Применение молекул, ингибирующих семафорин-4d, в комбинации с иммуномодулирующей терапией для ингибирования роста и метастазирования опухолей
EA201591632A1 (ru) Цитотоксические и антимитотические соединения и способы их применения
CL2016000408A1 (es) Composiciones farmaceuticas que contienen diastereomeros macrolidos, metodos para su sintesis y usos terapeuticos.
EA201690406A1 (ru) Селективные ингибиторы grp94 и способы их применения
ECSP11011297A (es) Proteinas ligadoras il-17
CL2012000583A1 (es) Compuestos derivados de quinazolinas sustituidas, inhibidores de los canales ionicos de potasio; composicion farmaceutica que los comprende; uso del compuesto para tratar o prevenir arritmias, controlar la frecuencia cardiaca, entre otras.
CY1120098T1 (el) Συνθεσεις που περιεχουν βορτιοξετινη και δονεπεζιλη
CL2023002108A1 (es) Proteínas unión multiespecíficas se unen a cd33, nkg2d, cd16, métodos de uso.
CL2013000400A1 (es) Conjugado de factor estimulante de colonia granulocito (g-csf) con polietilenglicol; composicion farmaceutica que lo contiene; y uso para la profilaxis o tratamiento de leucopenia.
BR112015022196A2 (pt) composições de liberação prolongada, que compreendem hidrocodona e acetaminofeno para rápido início e analgesia prolongada, que podem ser administradas independentemente de alimentos
CL2009001150A1 (es) Compuestos derivados de n-(2-amino-fenil)-acrilamidas, inhibidor de la histona-desacetilasa (hdac); procedimiento de preparacion; composicion faramceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CL2008001477A1 (es) Composicion farmaceutica compuesta por la combinacion sinergica de un agente anticonvulsivante como gabapentina y un agente antiinflamatorio no esteroideo como meloxicam, los rangos de concentracion presentes para la gabapentina son 3 a 300 mg y de 0,1 a 30 mg para meloxicam; y uso para tratar el dolor neuropatico
WO2017118822A3 (fr) Composés"multi-cibles"à activité inhibitrice des histone-désacétylases et de la polymérisation de la tubuline pour son utilisation dans le traitement du cancer
AR101736A1 (es) Composiciones que contienen zinc, con aceites esenciales

Legal Events

Date Code Title Description
FB Suspension of granting procedure